Zelebrudomide

Small molecule

Also known as NX-2127

Discontinuedsponsor decision

Evidence outlook · program status

Discontinued (2026-08), as a strategic decision by the sponsor

Nurix discontinued further clinical development of zelebrudomide (NX-2127) in a strategic prioritization of its oncology portfolio. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (1)
Other / comorbidity

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

No upcoming readouts on record for this asset.